<DOC>
	<DOCNO>NCT00267670</DOCNO>
	<brief_summary>The purpose study explore potential benefit medication , pentoxifylline , treatment NASH .</brief_summary>
	<brief_title>Pentoxifylline/Nonalcoholic Steatohepatitis ( NASH ) Study : The Effect Pentoxifylline NASH</brief_title>
	<detailed_description>This investigational study look subject diagnose nonalcoholic steatohepatitis ( NASH ) 'fatty liver disease ' . There currently FDA approve available treatment NASH . The purpose study explore potential benefit medication , pentoxifylline , treatment NASH . The effectiveness drug determine take blood sample liver biopsy . To determine effect medication , two-thirds patient participate study receive pentoxifylline one-third receive placebo ( sugar pill ) . Thus , individual 's chance receive drug 67 % . In addition receiving study drug ( placebo pentoxifylline ) subject encourage achieve modest weight loss ( ~1-2 lbs/week ) via low-fat diet exercise . The drug ( Pentoxifylline ) study approve use people NASH . Pentoxifylline consider experimental study . Pentoxifylline safely use treatment medical condition alcohol relate liver disease poor circulation . Pentoxifylline pill take three time day .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>1 . Subjects must willing give write informed consent 2 . Diagnosis steatohepatitis Grade &gt; = 1 ( Brunt et al . criterion Am J Gastroenterology 1999 ; 94 ( 9 ) 246774 ) biopsy within 6 month prior entry protocol 3 . No histologic evidence cirrhosis 4 . Persistent ALT elevation ( &gt; 1.5 upper limit normal ) 6 month prior entry study 5 . Adult subject 1865 year age race gender 6 . Compensated liver disease follow hematologic , biochemical , serological criterion entry protocol : Hemoglobin &gt; 11 gm/dL female &gt; 12 gm/dL male White blood cell ( WBC ) &gt; 2.5 K/UL Neutrophil count &gt; 1.5 K/UL Platelets &gt; 100 K/UL Direct bilirubin , within normal limit Indirect bilirubin within normal limit ( unless nonhepatitis factor Gilbert 's disease explain indirect bilirubin rise . In case total bilirubin must &lt; 3.0 mg/dL ) Albumin &gt; 3.2 g/dL Serum creatinine within normal limit 7 . Hemoglobin A1c ( HgbA1c ) &lt; 7 % 8 . Antinuclear antibody ( ANA ) &lt; 1:160 9 . Antismooth muscle Ab negative 10 . Serum hepatitis B surface antigen ( HepBsAg ) negative 11 . Serum hepatitis C antibody ( HepC Ab ) negative 12 . Iron/total iron binding capacity ( TIBC ) ratio ( transferrin saturation ) &lt; 45 % 13 . Alpha1antitrypsin level within normal limit 14 . Ceruloplasmin level within normal limit 15 . Negative pregnancy test ( female ) 16 . Concomitant use lipid lower agent study entry exclude patient study . 1 . Evidence decompensated cirrhosis 2 . Active gastrointestinal ( GI ) bleed 3 . Renal failure ( creatinine clearance &lt; 80 mL/min ) 4 . Active alcohol drug abuse 5 . Uncontrolled diabetes ( HgbA1c &gt; 7 ) 6 . Current treatment antidiabetic medication thiazolidinediones metformin ( stable dos sulfonylureas acceptable ) 7 . Current treatment antiTNF alpha medication ( i.e . Remicade Enbrel ) 8 . Current treatment vitamin E 9 . Alcohol consumption &lt; 20 g/day ( male ) &lt; 10 g/day ( female ) assess one physician confirm one family member . 10 . HIV positive status 11 . Any history cerebral and/or retinal hemorrhage 12 . Prior intolerance pentoxifylline methylxanthine ( i.e . caffeine , theophylline , theobromine ) 13 . Current use theophylline 14 . Known diagnosis malignancy 15 . Any condition investigator feel would make subject unsuitable enrollment , could interfere subject complete protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Fatty Liver Disease</keyword>
	<keyword>Liver</keyword>
	<keyword>NASH</keyword>
	<keyword>Nonalcoholic Steatohepatitis</keyword>
	<keyword>Nonalcoholic Fatty Liver Disease ( NAFLD )</keyword>
	<keyword>Pentoxifylline</keyword>
</DOC>